CER Could Lead To $10 Bil. Per Year Drop In R&D – Think Tank Analysis
Investments in drug and medical device research and development will decrease as comparative effectiveness research conducted under the Patient-Centered Outcomes Research Institute begins to gain traction, Benjamin Zycher, senior fellow at Pacific Research Institute, predicts.
You may also be interested in...
The credibility of comparative effectiveness research ultimately will be judged based on the methodology used to conduct the research, David Charles, associate professor and vice-chairman of neurology at Vanderbilt University Medical Center and chairman of the physician group Alliance for Patient Access, told attendees during a session at the Biotechnology Industry Organization International Convention.
NEW YORK – Although the list of topics to be researched with “tier 1” grants from the Patient-Centered Outcomes Research Institute will not be finalized until sometime in June, one area that is sure to garner funding opportunities will be finding ways to engage patients as stakeholders.
During the health care reform debate, much concern was expressed that results of comparative effectiveness research from the Patient-Centered Outcomes Research Institute could play a key role in Medicare coverage decisions. But CER has already been considered in making Medicare coverage decisions for years, recent Avalere Health analysis of national coverage determinations issued by CMS points out.